Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course and a booster dose in healthy children in Russia: a phase III, non-randomized, open-label study

Victor Romanenko, Irina Osipova, Anna Galustyan, Michael Scherbakov, Nathalie Baudson, Déborah Farhi, Luis Anaya, Sherine O Kuriyakose, Nadia Meyer, Winnie Janssens, Victor Romanenko, Irina Osipova, Anna Galustyan, Michael Scherbakov, Nathalie Baudson, Déborah Farhi, Luis Anaya, Sherine O Kuriyakose, Nadia Meyer, Winnie Janssens

Abstract

We assessed the immunogenicity and safety of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus/Haemophilus influenzae type b vaccine (DTPa-IPV/Hib) in children in Russian Federation aiming to support the registration of the vaccine in Russia. In this phase 3, non-randomized, open-label study (NCT02858440), healthy children received three primary doses at 3, 4.5, and 6 months of age (N = 235) and a booster dose at 18 months of age (N = 225). Seroprotection rates against diphtheria, tetanus, Hib, and poliovirus 1-3, seropositivity rates against pertussis antigens, and antibody geometric mean concentrations/titers for all antigens were evaluated one month post-primary and post-booster vaccinations. Solicited local and general adverse events (AEs) were collected during a 4-day period and unsolicited AEs during a 31-day period post-vaccination. Serious AEs were recorded throughout the study. At post-primary vaccination, all infants were seroprotected against diphtheria, tetanus, and poliovirus 1 and 2, 99.3% against poliovirus 3, and 98.4% against Hib. At least 98.9% of participants were seropositive for the three pertussis antigens. At post-booster vaccination, all toddlers were seroprotected/seropositive against all vaccine components. The most frequent local and general solicited AEs were redness, reported for 52.6% and 44.9% of children, and irritability, reported for 64.7% and 39.1% of children, post-primary and post-booster vaccination, respectively. Unsolicited AEs were reported for 20.4% (post-primary) and 5.8% of children (post-booster vaccination). Most AEs were mild or moderate in intensity. Six serious AEs were reported in three (0.4%) children; none were fatal or assessed as vaccination-related. DTPa-IPV/Hib proved immunogenic and well tolerated in the Russian pediatric population.

Keywords: DTPa-IPV/Hib; acellular pertussis; diphtheria; immunogenicity; pediatric population; poliovirus Haemophilus influenzae type b; reactogenicity; safety; tetanus.

Figures

Figure 1.
Figure 1.
Flow of participants N, number of participants; ATP, according-to-protocol. Note: participants may have more than one reason for exclusion.
Figure 2.
Figure 2.
Solicited adverse events (total vaccinated cohorts) N, number of participants for primary and booster vaccination course with at least one documented dose.
Figure 2.
Figure 2.
Solicited adverse events (total vaccinated cohorts) N, number of participants for primary and booster vaccination course with at least one documented dose.
Figure 3.
Figure 3.
Plain language summary.

References

    1. Gentile A, Bhutta Z, Bravo L, Samy AG, Garcia RD, Hoosen A, Islam T, Karimi A, Salem M, Simasathien S, et al. Pediatric disease burden and vaccination recommendations: understanding local differences. Int J Infect Dis. 2010;14:e649–658. doi:10.1016/j.ijid.2009.11.006.
    1. WHO . Haemophilus influenzae type b (Hib) vaccination position paper - July 2013. Wkly Epidemiol Rec. 2013;88:413–26.
    1. WHO . Pertussis vaccines: WHO position paper - September 2015. Wkly Epidemiol Rec. 2015;90:433–58.
    1. WHO . Polio vaccines: WHO position paper - March, 2016. Wkly Epidemiol Rec. 2016;91:145–68.
    1. WHO . Diphtheria vaccine: WHO position paper - August 2017. Wkly Epidemiol Rec. 2017;92:417–35.
    1. WHO . Tetanus vaccines: WHO position paper - February 2017. Wkly Epidemiol Rec. 2017;92:53–76.
    1. Sealey KL, Belcher T, Preston A.. Bordetella pertussis epidemiology and evolution in the light of pertussis resurgence. Infect Genet Evol. 2016;40:136–43. doi:10.1016/j.meegid.2016.02.032.
    1. Kalies H, Grote V, Verstraeten T, Hessel L, Schmitt H-J, von Kries R.. The use of combination vaccines has improved timeliness of vaccination in children. Pediatr Infect Dis. 2006;25:507–12. doi:10.1097/01.inf.0000222413.47344.23.
    1. Maman K, Zollner Y, Greco D, Duru G, Sendyona S, Remy V. The value of childhood combination vaccines: from beliefs to evidence. Hum Vaccin Immunother. 2015;11:2132–41. doi:10.1080/21645515.2015.1044180.
    1. Marshall GS, Happe LE, Lunacsek OE, Szymanski MD, Woods CR, Zahn M, Russell A. Use of combination vaccines is associated with improved coverage rates. Pediatr Infect Dis J. 2007;26:496–500. doi:10.1097/INF.0b013e31805d7f17.
    1. Skibinski DA, Baudner BC, Singh M, O’Hagan DT. Combination vaccines. J Glob Infect Dis. 2011;3:63–72. doi:10.4103/0974-777x.77298.
    1. Anh DD, Van Der Meeren O, Karkada N, Assudani D, Yu TW, Han HH. Safety and reactogenicity of the combined diphtheria-tetanus-acellular pertussis-inactivated poliovirus-Haemophilus influenzae type b (DTPa-IPV/Hib) vaccine in healthy Vietnamese toddlers: an open-label, phase III study. Hum Vaccin Immunother. 2016;12:655–57. doi:10.1080/21645515.2015.1084451.
    1. Halperin SA, King J, Law B, Mills E, Willems P. Safety and immunogenicity of Haemophilus influenzae-tetanus toxoid conjugate vaccine given separately or in combination with a three-component acellular pertussis vaccine combined with diphtheria and tetanus toxoids and inactivated poliovirus vaccine for the first four doses. Clin Infect Dis. 1999;28:995–1001. doi:10.1086/514741.
    1. Kim KH, Kim CS, Kim HM, Kim JD, Ma SH, Kim DH, Hwang PH, Han JW, Lee TJ, Kim JH, et al. Immunogenicity and safety of a combined DTPa-IPV/Hib vaccine administered as a three-dose primary vaccination course in healthy Korean infants: phase III, randomized study. Hum Vaccin Immunother. 2019;15:317–26. doi:10.1080/21645515.2018.1536588.
    1. Li Y, Li RC, Ye Q, Li C, Liu YP, Ma X, Li Y, Zhao H, Chen X, Assudani D, et al. Safety, immunogenicity and persistence of immune response to the combined diphtheria, tetanus, acellular pertussis, poliovirus and Haemophilus influenzae type b conjugate vaccine (DTPa-IPV/Hib) administered in Chinese infants. Hum Vaccin Immunother. 2017;13:588–98. doi:10.1080/21645515.2016.1239670.
    1. Lin TY, Wang YH, Chang LY, Chiu CH, Huang YC, Tang H, Bock HL. Safety and immunogenicity of a diphtheria, tetanus, and acellular pertussis-inactivated poliovirus vaccine/Haemophilus influenzae type B combination vaccine administered to Taiwanese infants at 2, 4, and 6 months of age. Chang Gung Med J. 2003;26:315–22.
    1. Phua KB, Quak SH, Lim FS, Goh P, Teoh YL, Datta SK, Han HH, Bock HL. Immunogenicity, reactogenicity and safety of a diphtheria-tetanus-acellular pertussis-inactivated polio and Haemophilus influenzae type b vaccine in a placebo-controlled rotavirus vaccine study. Ann Acad Med Singapore. 2008;37:546–53.
    1. Order of the Ministry of Health of the Russian Federation N252n . On approval of the national immunization schedule and immunization schedule due to epidemic indications. Registered in the Ministry of Justice of the Russian Federation, registration number 32115 (as of June 20, 2013). 2014.
    1. WHO vaccine-preventable diseases: monitoring system . 2018 global summary. [accessed 2019 July2]. .
    1. Camargo ME, Silveira L, Furuta JA, Oliveira EP, Germek OA. Immunoenzymatic assay of anti-diphtheric toxin antibodies in human serum. J Clin Microbiol. 1984;20:772–74. doi:10.1128/JCM.20.4.772-774.1984.
    1. Melville-Smith ME, Seagroatt VA, Watkins JT. A comparison of enzyme-linked immunosorbent assay (ELISA) with the toxin neutralization test in mice as a method for the estimation of tetanus antitoxin in human sera. J Biol Stand. 1983;11:137–44. doi:10.1016/s0092-1157(83)80038-9.
    1. Granstrom M, Thoren M, Blennow M, Tiru M, Sato Y. Acellular pertussis vaccine in adults: adverse reactions and immune response. Eur J Clin Microbiol. 1987;6:18–21. doi:10.1007/bf02097184.
    1. Karpinski KF, Hayward S, Tryphonas H. Statistical considerations in the quantitation of serum immunoglobulin levels using the enzyme-linked immunosorbent assay (ELISA). J Immunol Methods. 1987;103:189–94. doi:10.1016/0022-1759(87)90289-4.
    1. Immunization WHOEPo . Guidelines for WHO/EPI collaborative studies on poliomyelitis: standard procedure for determining immunity to poliovirus using the microneutralization test. Geneva, Switzerland: World Health Organization; 1993.
    1. Kayhty H, Peltola H, Karanko V, Makela PH. The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b. J Infect Dis. 1983;147:1100. doi:10.1093/infdis/147.6.1100.
    1. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17:1055–65. doi:10.1128/cvi.00131-10.
    1. Plotkin SA. Updates on immunologic correlates of vaccine-induced protection. Vaccine. 2019; doi:10.1016/j.vaccine.2019.10.046.
    1. Medical Dictionary for Regulatory Activities . [accessed 2019 August14]. .
    1. Aristegui J, Dal-Re R, Diez-Delgado J, Mares J, Casanovas JM, Garcia-Corbeira P, De Frutos E, Van Esso D, Verdaguer J, De la Flor J, et al. Comparison of the reactogenicity and immunogenicity of a combined diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated polio (DTPa-HBV-IPV) vaccine, mixed with the Haemophilus influenzae type b (Hib) conjugate vaccine and administered as a single injection, with the DTPa-IPV/Hib and hepatitis B vaccines administered in two simultaneous injections to infants at 2, 4 and 6 months of age. Vaccine. 2003;21:3593–600. doi:10.1016/S0264-410X(03)00420-1.
    1. Shao PL, Lu CY, Hsieh YC, Bock HL, Huang LM. Immunogenicity and reactogenicity of DTPa-IPV/Hib vaccine co-administered with hepatitis B vaccine for primary and booster vaccination of Taiwanese infants. J Formos Med Assoc. 2011;110:415–22. doi:10.1016/s0929-6646(11)60061-2.
    1. Schmitt HJ, Knuf M, Ortiz E, Sanger R, Uwamwezi MC, Kaufhold A. Primary vaccination of infants with diphtheria-tetanus-acellular pertussis-hepatitis B virus- inactivated polio virus and Haemophilus influenzae type b vaccines given as either separate or mixed injections. J Pediatr. 2000;137:304–12. doi:10.1067/mpd.2000.107796.
    1. Eskola J, Ward J, Dagan R, Goldblatt D, Zepp F, Siegrist CA. Combined vaccination of Haemophilus influenzae type b conjugate and diphtheria-tetanus-pertussis containing acellular pertussis. Lancet. 1999;354:2063–68. doi:10.1016/s0140-6736(99)04377-9.
    1. Poolman J, Kaufhold A, De Grave D, Goldblatt D. Clinical relevance of lower Hib response in DTPa-based combination vaccines. Vaccine. 2001;19:2280–85. doi:10.1016/s0264-410x(00)00517-x.
    1. Wang S, Tafalla M, Hanssens L, Dolhain J. A review of Haemophilus influenzae disease in Europe from 2000–2014: challenges, successes and the contribution of hexavalent combination vaccines. Expert Rev Vaccines. 2017;16:1095–105. doi:10.1080/14760584.2017.1383157.
    1. Avdicová M, Prikazský V, Hudecková H, Schuerman L, Willems P. Immunogenicity and reactogenicity of a novel hexavalent DTPa-HBV-IPV/Hib vaccine compared to separate concomitant injections of DTPa-IPV/Hib and HBV vaccines, when administered according to a 3, 5 and 11 month vaccination schedule. Eur J Pediatr. 2002;161:581–87. doi:10.1007/s00431-002-1079-5.
    1. Heininger U, Sanger R, Jacquet JM, Schuerman L. Booster immunization with a hexavalent diphtheria, tetanus, acellular pertussis, hepatitis B, inactivated poliovirus vaccine and Haemophilus influenzae type b conjugate combination vaccine in the second year of life: safety, immunogenicity and persistence of antibody responses. Vaccine. 2007;25:1055–63. doi:10.1016/j.vaccine.2006.09.060.
    1. Lim FS, Phua KB, Lee BW, Quak SH, Teoh YL, Ramakrishnan G, Han HH, Van Der Meeren O, Jacquets JM, Bock HL. Safety and reactogenicity of DTPa-HBV-IPV/Hib and DTPa-IPV/I-Hib vaccines in a post-marketing surveillance setting. Southeast Asian J Trop Med Public Health. 2011;42:138–47.
    1. Avdicova M, Crasta PD, Hardt K, Kovac M. Lasting immune memory against hepatitis B following challenge 10-11 years after primary vaccination with either three doses of hexavalent DTPa-HBV-IPV/Hib or monovalent hepatitis B vaccine at 3, 5 and 11-12 months of age. Vaccine. 2015;33:2727–33. doi:10.1016/j.vaccine.2014.06.070.
    1. Zepp F, Schmitt HJ, Cleerbout J, Verstraeten T, Schuerman L, Jacquet JM. Review of 8 years of experience with Infanrix hexa (DTPa-HBV-IPV/Hib hexavalent vaccine). Expert Rev Vaccines. 2009;8:663–78. doi:10.1586/erv.09.32.
    1. WHO and UNICEF estimates of national routine immunization coverage, 2017 revision (completed July 2018). [accessed 2019 July2]. .
    1. Organisation for Economic Co-operation and Development (OECD) Data . Child vaccination rates. [accessed 2019 August6]. .
    1. Kurova N, Timofeeva EV, Guiso N, Macina D. A cross-sectional study of Bordetella pertussis seroprevalence and estimated duration of vaccine protection against pertussis in St. Petersburg, Russia. Vaccine. 2018;36:7936–42. doi:10.1016/j.vaccine.2018.11.007.
    1. WHO. Pertussis vaccines: WHO position paper, August 2015. Wkly Epidemiol Rec. 2016;90:433–60.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel